Hereditary Angioedema Therapeutic Market Size, Share, Competitive Landscape and Trend Analysis Report, by Route of Administration and, by Treatment : Global Opportunity Analysis and Industry Forecast, 2023-2032

Hereditary Angioedema (HAE) is an inherited condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous or submucosal swelling without the presence of urticarial lesions due to C1 protein inhibition. C1 inhibition leads to accumulation of Bradikynin, which leads to fluid leakage. Lymphatic or blood flow, constant accumulation of liquids outside of the veins, brings about swelling of tissues in the feet, arms, intestinal tract, airway, or face. Hereditary Angioedema might be obtained or acquired; it is more common in youngsters.  Multiple areas of the body can be involved including hands, feet, intestinal wall, genitalia, face, tongue, or larynx.¹ Swelling of the pharynx or larynx can be life–threatening due to asphyxia. Hereditary Angioedema is a burdensome disease that can lead to debilitating and dangerous Angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects.

Impact of Covid-19 on market:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine, have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Market Scenario Analysis- Drivers, Opportunities, Risks and Challenge Factors:

The increase in awareness due to government initiatives, improved management, and better outcomes and rise in demand for preventive care are few of the market driving factors. Shift toward gene therapy is one of the recent opportunities available in the Hereditary Angioedema Therapeutic market. Also, the government recommendation for drugs recently available is also rising opportunities. Delay in effective treatment due to appendicitis and other such allergies acts as a market restraint factor.

Hereditary Angioedema Therapeutic market growth is hampered due to high cost of drugs as well. The risk of thrombosis associated with C1-inhibitor (C1-INH), worsening attacks with fresh frozen plasma (FFP) and carcinoma secondary to androgens (mainly danazol) are few of the market restraint factors. To develop better medicines with no side effects is a challenge in the market.

Rise in demand of Subcutaneous Injection:

Subcutaneous injections are highly effective in administering medications such as insulin, morphine, diacetylmorphine and goserelin. Rise in demand of easy-usage for patients is estimated to increase demand of subcutaneous injections as a mode of drug administration.

New Therapies & Innovations Contributing to Hereditary Angioedema Treatment Market Growth:

The R&D segment is estimated to drive the Hereditary Angioedema Therapeutic market growth rapid increase in the development of drugs for hereditary angioedema treatment. In August 2018, The US Food and Drug Administration (FDA) approved lanadelumab (Takhzyro, Shire). It is the first monoclonal antibody to help prevent attacks of hereditary angioedema (HAE) in patients. In June 2017, CSL Behring developed drug namely Haegarda® (C1 Esterase Inhibitor) was approved by FDA. It is a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

Key Benefits of the Report:

• This study presents the analytical depiction of the global Hereditary Angioedema Therapeutic market along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Hereditary Angioedema Therapeutic market share.
• The current market is quantitatively analyzed to highlight the global Hereditary Angioedema Therapeutic market growth scenario.
• The report provides a detailed global Hereditary Angioedema Therapeutic market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Hereditary Angioedema Therapeutic Market research report:

• Which are the leading market players active in the Hereditary Angioedema Therapeutic market?
• What are the driving factors, challenges, and opportunities in the Hereditary Angioedema Therapeutic market?
• What are the different market segments in this Hereditary Angioedema Therapeutic market?
• What are the projections for the future that would help in taking further strategic steps?

  Hereditary Angioedema Therapeutic Market Report Highlights

Aspects	Details
By Route of Administration	Intravenous Subcutaneous Oral
By Treatment	Short Term Prophylaxis Long Term Prophylaxis
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Adverum Biotechnologies, Inc., Takeda Pharmaceutical Company Limited,, Takeda Pharmaceutical Company,, Attune Pharmaceuticals, Inc.,, Pharming Healthcare, Inc.,, CSL Behring,, Ionis Pharmaceuticals,, KalVista Pharmaceuticals, Inc.,, Shire Plc., BioCryst Pharmaceuticals, Inc.,

^*Terms and Conditions Apply